Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H23NO2 |
Molecular Weight | 273.37 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)[C@@]1(CCC=C[C@H]1N(C)C)C2=CC=CC=C2
InChI
InChIKey=WDEFBBTXULIOBB-WBVHZDCISA-N
InChI=1S/C17H23NO2/c1-4-20-16(19)17(14-10-6-5-7-11-14)13-9-8-12-15(17)18(2)3/h5-8,10-12,15H,4,9,13H2,1-3H3/t15-,17+/m1/s1
Molecular Formula | C17H23NO2 |
Molecular Weight | 273.37 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
The opiate-like action of tilidine is mediated by metabolites. | 1978 Sep |
|
Antagonism between tilidine and naloxone on cerebral potentials and pain ratings in man. | 1983 Mar 4 |
|
[Erroneous intravenous injection of adrenaline]. | 1998 May 29 |
|
Actions of tilidine and nortilidine on cloned opioid receptors. | 2005 Jan 4 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15627429
The selectivity of tilidine and nortilidine for human opioid and opioid-like receptors stably expressed in CHO-K1 cells, using the inhibition of the forskolin (FK)-induced accumulation of cAMP as the endpoint was measured. In cells expressing the Mu opioid receptor, tilidine and nortilidine inhibited cAMP accumulation with IC50 of 11 microM and 110 nM, respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 14:59:30 GMT 2023
by
admin
on
Fri Dec 15 14:59:30 GMT 2023
|
Record UNII |
GY33N31E9Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
||
|
WHO-VATC |
QN02AX01
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
||
|
NCI_THESAURUS |
C241
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
||
|
DEA NO. |
9750
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
||
|
WHO-ATC |
N02AX01
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2663
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY | |||
|
DB13787
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY | |||
|
D013993
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY | |||
|
243-774-7
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
ALTERNATIVE | |||
|
10597
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY | RxNorm | ||
|
GY33N31E9Y
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY | |||
|
m10864
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
257-522-9
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY | |||
|
100000082696
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY | |||
|
TILIDINE
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY | |||
|
20380-58-9
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
SUPERSEDED | |||
|
51931-66-9
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY | |||
|
C152628
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY | |||
|
SUB11051MIG
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY | |||
|
2510
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY | |||
|
77823
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL2220384
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY | |||
|
30131
Created by
admin on Fri Dec 15 14:59:30 GMT 2023 , Edited by admin on Fri Dec 15 14:59:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
TARGET->WEAK AGONIST |
Inhibition of forskolin-induced cAMP accumulation
IC50
|
||
|
ACTIVE ENANTIOMER->RACEMATE |
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
||
|
METABOLITE ACTIVE -> PRODRUG |
After oral intake tilidine is completely absorbed and rapidly metabolised to nortilidine, bisnortilidine. 100 fold more active than Tilidine.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|